Puma Biotechnology, Inc.
PBYI
$7.17
$0.091.27%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.59% | 27.72% | -32.36% | 11.37% | 5.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.59% | 27.72% | -32.36% | 11.37% | 5.12% |
| Cost of Revenue | -1.25% | 66.13% | -58.16% | 15.42% | -1.60% |
| Gross Profit | -2.99% | 15.88% | -17.77% | 10.19% | 7.30% |
| SG&A Expenses | 4.65% | 10.57% | -0.01% | -27.73% | -19.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.75% | 27.64% | -23.20% | -7.03% | -8.77% |
| Operating Income | -196.08% | 27.99% | -56.64% | 404.54% | 273.29% |
| Income Before Tax | -204.90% | 39.79% | -55.15% | 248.52% | 171.10% |
| Income Tax Expenses | 11.26% | 151.92% | 37.11% | -17.99% | 33.18% |
| Earnings from Continuing Operations | -226.19% | -30.39% | -56.47% | 229.28% | 161.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -226.19% | -30.39% | -56.47% | 229.28% | 161.77% |
| EBIT | -196.08% | 27.99% | -56.64% | 404.54% | 273.29% |
| EBITDA | -118.35% | 28.08% | -50.74% | 1,189.30% | 1,033.78% |
| EPS Basic | -223.00% | -32.12% | -57.62% | 225.59% | 160.06% |
| Normalized Basic EPS | -202.18% | 36.33% | -56.32% | 244.32% | 169.13% |
| EPS Diluted | -223.00% | -34.44% | -58.54% | 225.59% | 160.00% |
| Normalized Diluted EPS | -202.93% | 34.04% | -56.70% | 243.02% | 168.62% |
| Average Basic Shares Outstanding | 2.52% | 2.53% | 2.72% | 2.92% | 2.92% |
| Average Diluted Shares Outstanding | 1.88% | 4.28% | 3.57% | 3.84% | 3.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |